Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives $19.00 Consensus Target Price from Analysts

Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) have received a consensus rating of “Moderate Buy” from the six analysts that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, four have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $19.00.

ARTV has been the subject of a number of recent analyst reports. Wedbush raised their price objective on shares of Artiva Biotherapeutics from $18.00 to $23.00 and gave the stock an “outperform” rating in a research note on Friday, October 17th. Needham & Company LLC restated a “buy” rating and issued a $18.00 target price on shares of Artiva Biotherapeutics in a report on Friday, October 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research report on Tuesday, January 27th. HC Wainwright lifted their price target on Artiva Biotherapeutics from $12.00 to $15.00 and gave the company a “buy” rating in a report on Wednesday, November 12th. Finally, Jefferies Financial Group raised Artiva Biotherapeutics to a “strong-buy” rating in a research note on Tuesday, November 18th.

Artiva Biotherapeutics Trading Down 1.0%

NASDAQ ARTV opened at $3.85 on Thursday. Artiva Biotherapeutics has a 1 year low of $1.47 and a 1 year high of $7.36. The company has a market cap of $94.50 million, a PE ratio of -1.49 and a beta of 2.92. The stock’s 50-day moving average price is $4.27 and its two-hundred day moving average price is $3.60.

Artiva Biotherapeutics (NASDAQ:ARTV) last released its earnings results on Wednesday, November 12th. The company reported ($0.88) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.04. Research analysts forecast that Artiva Biotherapeutics will post -4.95 EPS for the current fiscal year.

Institutional Trading of Artiva Biotherapeutics

Institutional investors have recently made changes to their positions in the stock. Citadel Advisors LLC grew its position in Artiva Biotherapeutics by 419.3% during the third quarter. Citadel Advisors LLC now owns 798,397 shares of the company’s stock valued at $2,291,000 after purchasing an additional 644,658 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in shares of Artiva Biotherapeutics by 14,463.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock valued at $340,000 after buying an additional 117,733 shares during the period. Marshall Wace LLP purchased a new position in shares of Artiva Biotherapeutics during the 2nd quarter valued at $79,000. Jane Street Group LLC acquired a new position in shares of Artiva Biotherapeutics in the second quarter worth $67,000. Finally, Landscape Capital Management L.L.C. acquired a new position in shares of Artiva Biotherapeutics in the third quarter worth $112,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.